Clinical Trial Update: Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL). [Phase 1, Phase 2]

View source ↗

Summary

The document updates on an ongoing clinical trial of GYA01 (CART84) for relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia, with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• T-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• GYA01 (CART84) (CART84)

Snippet

Sponsor: Gyala Therapeutics | Conditions: Acute Myeloblastic Leukaemia, Leukemia, T-Cell | Phase 1, Phase 2 | Status: RECRUITING